NIPRO Launches FDA-Cleared ELISIO-HX Dialyzer in U.S.
Osaka, Japan and Bridgewater, New Jersey, August 4, 2026 NIPRO CORPORATION, through its U.S.-based subsidiary NIPRO Medical Corporation, has...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Osaka, Japan and Bridgewater, New Jersey, August 4, 2026 NIPRO CORPORATION, through its U.S.-based subsidiary NIPRO Medical Corporation, has...
OSAKA, Japan, July 30, 2026 NIPRO CORPORATION has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...
INCHEON, South Korea, May 20, 2026 Samsung Bioepis has announced the official launch of Ustekinumab BS 45 mg Syringe...
